Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Check out some of our latest original content that was created and distributed as part of our ongoing collaborations with IR firms and other companies.

MissionIRNewsBreaks – Eloro Resources Ltd. (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM) Positioned to Capitalize on Forthcoming Resources Discoveries

Posted on March 28, 2023 by MissionIR

Eloro Resources (TSX: ELO) (OTCQX: ELRRF) (FSE: P2QM), an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec, recently commenced trading on the Toronto Stock Exchange (“TSX”). “The upgrade [from the TSX Venture Exchange] in its stock listing marks the latest feat for Eloro Resources, with the company having announced earlier in January that it had concluded its fully underwritten primary share placement, raising total gross proceeds of C$10,919,570. At the time, the company revealed that the net proceeds derived from the offering would be destined toward exploration and development purposes at the company’s ongoing mining project in Bolivia as well as for general working capital purposes. Since commencing its inaugural drill program at the Iska Iska site in September 2020, Eloro Resources has completed a cumulative 84,495 meters of drilling across 122 holes at Iska Iska, with the company anticipating the publication of the initial estimates by the end of March 2023,” a recent article reads. “Following the company’s uplisting to the Toronto Stock Exchange main board, successful capital exercise, and benefiting from exponential demand growth for both silver and tin as a result of the ongoing global transition toward renewable energy sources, Eloro Resources looks well placed to capitalize on any forthcoming resources discoveries in the coming months.”

To view the full article, visit https://ibn.fm/TxdtN

About Eloro Resources Ltd.

Eloro is an exploration and mine development company with a portfolio of gold and base-metal properties in Bolivia, Peru and Quebec. Through its Bolivian subsidiary, Eloro has an option to acquire a 100% interest in the highly prospective Iska Iska Property, which can be classified as a polymetallic epithermal-porphyry complex, a significant mineral deposit type in the Potosi Department, in southern Bolivia. A recent NI 43-101 Technical Report on Iska Iska, which was completed by Micon International Limited, is available on Eloro’s website and under its filings on SEDAR. Iska Iska is a road-accessible, royalty-free property. Eloro also owns an 82% interest in the La Victoria Gold/Silver Project, located in the North-Central Mineral Belt of Peru some 50 km south of Barrick’s Lagunas Norte Gold Mine and Pan American Silver’s La Arena Gold Mine.

NOTE TO INVESTORS: The latest news and updates relating to ELRRF are available in the company’s newsroom at https://ibn.fm/ELRRF

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Eloro Resources Ltd. ELRRF | Leave a comment

MissionIRNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Files Lawsuit for Damages Sustained from False Article

Posted on March 28, 2023 by MissionIR

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today announced that it has filed a civil complaint for defamation in the Superior Court of Delaware. The complaint alleges that on March 22, 2023, Intersection Media Group, d/b/a dot.LA, published an article on its website authored by David Shultz that contained false and defamatory statements regarding Mullen, including false and defamatory statements regarding the terms of a settlement agreement of a civil action. The company has retained McDermott Will & Emery LLP, a leading international law firm, to represent Mullen in the lawsuit.

To view the full news release, visit https://ibn.fm/JJ63l

About Mullen Automotive Inc.

Mullen is a Southern California-based automotive company building the next generation of electric vehicles (“EVs”) that will be manufactured in its two United States-based assembly plants. Mullen’s EV development portfolio includes the Mullen FIVE EV Crossover, Mullen I-GO Commercial Urban Delivery EV, Mullen Commercial Class 1-3 EVs and Bollinger Motors, which features both the B1 and B2 electric SUV trucks and Class 4-6 commercial offerings. On Sept. 7, 2022, Bollinger Motors became a majority-owned EV truck company of Mullen Automotive, and on Dec. 1, 2022, Mullen closed on the acquisition of all of Electric Last Mile Solutions’ (“ELMS”) assets, including all IP and a 650,000-square-foot plant in Mishawaka, Indiana. To learn more about the company, visit www.MullenUSA.com.

NOTE TO INVESTORS: The latest news and updates relating to MULN are available in the company’s newsroom at https://ibn.fm/MULN

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Mullen Automotive Inc. MULN | Leave a comment

Silo Pharma Inc. (NASDAQ: SILO) Provides Update on Innovative Study Looking into the Feasibility of Using Ketamine Formulations as an Alternative Treatment for Fibromyalgia

Posted on March 28, 2023 by MissionIR
  • Silo Pharma recently provided an update on an ongoing study delving into the potential use of SP-26 as an alternative treatment for fibromyalgia
  • The study, which is being carried out in conjunction with Experimur, has looked into the feasibility of using a time-released, dosage-controlled formulation of ketamine as a suitable treatment for the chronic medical condition
  • Since its founding, Silo Pharma has rapidly gained a reputation for its innovative approach towards seeking solutions to address a variety of underserved medical conditions

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently announced that it had achieved a positive outcome for its toxicology study of SP-26, its novel time-released, dosage-controlled formulation of ketamine. The results come after Silo Pharma had previously revealed that it was working on the preparation of a pre-Investigational New Drug (“IND”) package and meeting request with the US Food and Drug Administration (“FDA”) for a novel formulation of ketamine destined towards the treatment of fibromyalgia (https://ibn.fm/X5GM4).

At the time, Eric Weisblum, Silo Pharma’s Chief Executive Officer had remarked on the company’s efforts, “We are confident that our highly constructive pre-clinical work on SP-26 will offer strong support for our pre-IND package as we seek to advance our time-released ketamine delivery system into the clinic” (https://ibn.fm/tHFlD).

Fibromyalgia is a chronic condition causing pain to the connective tissues through the body including muscles, ligaments and tendons. Musculoskeletal pain is often accompanied by sleep difficulties, fatigue, mood disorders and problems with memory and concentration. Despite having over four million Americans living with fibromyalgia, there is relatively little known about this condition, and no apparent physical cause has been identified thus far. As of 2020, the FDA had approved three drugs specifically for treating fibromyalgia, however these have primarily been destined towards the treatment of specific symptoms, such as depression or nerve pain, rather than acting as a more holistic treatment (https://ibn.fm/k1mMN).

Now and in collaboration with Experimur, a Frontage Laboratories company, Silo Pharma have provided an update as to their efforts in producing a ketamine-based treatment for fibromyalgia. The company detailed in a recent announcement that it had tested SP-26 in a toxicology and tolerability study in mini pigs using an ascending (descending) dosing regimen. The study was carried out in adherence to the bioanalytical methods required to perform toxicology studies by the U.S. Food and Drug Administration (“FDA”) in advance of initiating clinical studies for SP-26.

“Today’s positive results are an important step as we move closer to achieving all needed components to plan human trials of SP-26.” remarked Weisblum. “We are advancing our work with our regulatory partners to prepare a Pre-Investigational New Drug (‘IND’) package for SP-26 and intend to pursue the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval.”

Originally founded in 2010, Silo Pharma has rapidly earned a reputation in recent years for its ground-breaking research into conditions such as post-traumatic stress disorder (“PTSD”), fibromyalgia, Alzheimer’s disease, Parkinson’s disease, and other rare neurological disorders. In addition to its recent research into potential fibromyalgia treatment alternatives, Silo Pharma have also been involved in a number of studies designed to develop innovative solutions for previously underserved conditions, including exploring the use of a prophylactic treatment for drug-resistant depression and delving into the effects of psilocybin on inflammation, among several other initiatives.

For more information, visit the company’s website at www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all

Posted in Silo Pharma Inc. SILO | Leave a comment

MissionIRNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) to Host Town Hall Marathon

Posted on March 27, 2023 by MissionIR

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots and blue light emergency communication systems, today announced its plans to hold 10 Town Halls during the first 10 days of April 2023. The event series is in celebration of Knightscope’s 10 year anniversary and following the filing of its 10-K annual report.

The announcement reads, “Similar to numerous prior Town Halls hosted by the company over the years, Knightscope’s Chairman and CEO, William Santana Li, will be available to answer questions from supporters, investors and analysts in an intimate online forum with no moderator. In order to accommodate busy schedules of our supporters, numerous time slots are available both weekdays and weekends as well as day and evening.”

To attend a Town Hall session, visit www.knightscope.com/rise

To view the full press release, visit https://ibn.fm/Oef6R

About Knightscope, Inc.

Knightscope is an advanced security technology company based in Silicon Valley that builds fully autonomous security robots that deter, detect and report. Knightscope’s long-term ambition is to make the United States of America the safest country in the world. For more information, visit the company’s website at www.knightscope.com.

NOTE TO INVESTORS: The latest news and updates relating to Knightscope are available in the company’s newsroom at https://ibn.fm/KSCP

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Knightscope Inc. KSCP | Leave a comment

CISO Global Inc. (NASDAQ: CISO) Committed to Building Client Trust, Attains ‘Highest Standard’ with SOC 2 Certification

Posted on March 27, 2023 by MissionIR
  • CISO achieves SOC 2 Type II certification following annual audit
  • President says company is committed to building relationships of trust with clients
  • Achieving certification symbolizes commitment to safeguarding customers’ data

As an industry leader in global cybersecurity and compliance services, CISO Global (NASDAQ: CISO), formerly Cerberus Cyber Sentinel Corp., recently reached a significant milestone (https://ibn.fm/BNFYO). The company announced that it has achieved SOC 2(R) Type II certification following its annual SOC 2 Type II audit.

“We believe that the relationship with our clients must be built on trust,” said Ashley Devoto, president and chief information security officer of Cerberus Sentinel. “As companies increase their usage of vendors and partners to perform activities that are core to their business operations and strategies, there is a need for the highest level of confidence and transparency into service providers’ abilities to safeguard customer data.”

Achieving the SOC 2 Type II certification, which was confirmed by an independent audit, is symbolic of Cerberus Sentinel’s commitment to providing the highest level of protection and honoring clients’ trust. The certification validates that Cerberus security controls and data-privacy practices meet best practices.

Cerberus Sentinel continues to strengthen its reputation as a managed cybersecurity and compliance provider that can be trusted to secure its customers’ systems. The SOC 2 Type II certification is widely recognized as a symbol of trust and excellence. This certification involves an in-depth review of controls relevant to security, availability, processing integrity, confidentiality and privacy and provides compliance attestation for service providers worldwide.

Typically, a SOC 2 audit is performed by an accredited CPA firm in accordance with the American Institute of Certified Public Accountants’ (“AICPA”) AT-C 205, “Reporting on Controls at a Service Organization,” and is based on the trust service principles outlined in the AICPA Guide “Reporting on Controls at a Service Organization Relevant to Security, Availability, Processing Integrity, Confidentiality, or Privacy.” The company noted that “achieving this standard with an unqualified opinion serves as third-party industry validation that Cerberus Sentinel manages customers’ data with the highest standard of security and compliance.”

Cerberus Sentinel is an industry leader in its role as a global cybersecurity and compliance provider. The company is rapidly expanding by acquiring world-class cybersecurity, secured managed services and compliance companies with top-tier talent that utilize the latest technology to create innovative solutions to protect the most demanding businesses and government organizations, mitigating continuing and emerging security threats and compliance obligations.

For more information, visit the company’s website at www.CISO.Inc.

NOTE TO INVESTORS: The latest news and updates relating to CISO are available in the company’s newsroom at https://ibn.fm/CISO

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all

Posted in Cerberus Cyber Sentinel Corp. CISO | Leave a comment

MissionIRNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent for Treatment of Fibromyalgia

Posted on March 27, 2023 by MissionIR

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that it has filed a provisional patent application titled “Methods and Compositions for Pain Management.” The methods and compositions described in the patent application can be used in ameliorating pain, including chronic pain such as fibromyalgia, which is a chronic condition that occurs in approximately 2% of the United States general population. Fibromyalgia is the initial target indication for the company’s drug, SP-26. “This provisional patent application supports our multi-pronged strategy for advancing SP-26 into the clinic,” said Silo Pharma CEO Eric Weisblum. “The company is working towards submitting an IND package to the FDA and pursuing the 505(b)(2) regulatory pathway for SP-26. We believe our drug would serve a critical need in a largely inadequate treatment landscape for chronic pain including fibromyalgia.”

To view the full press release, visit https://ibn.fm/oxLFb

About Silo Pharma Inc.

Silo Pharma is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which it believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit www.SiloPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at https://ibn.fm/SILO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Silo Pharma Inc. SILO | Leave a comment

Answer to Global Warming Isn’t Always Cars, It’s Trash and EverGen Infrastructure Corp. (TSX.V: EVGN) (OTCQX: EVGIF) Has a Solution

Posted on March 27, 2023 by MissionIR
  • Food waste contributed 9.3 billion metric tons of CO2-equivalent emissions in 2017, an amount equal to the total emission from the U.S. and E.U. that year
  • EverGen Infrastructure is a leading independent renewable energy producer with operations and a platform for converting organic waste in green energy and products
  • EverGen’s Sea to Sky Soils signed waste processing contracts with a B.C. regional district, an important step towards a goal of processing 300,000 tons of organic waste per annum in the region

There is finger pointing everywhere to single-out culprits in climate change, and exhaust-spewing fossil fuel-powered cars are an easy target. The reality is that, while it may sound great in theory, simply replacing all the cars on the road with electric alternatives carries several challenges related to infrastructure and battery materials. While the EV transition should remain a focus to address hurdles, an emphasis on responsible waste management can have an immediate impact on decarbonization.

Waste-to-energy technologies, such as those of EverGen Infrastructure’s (TSX.V: EVGN) (OTCQX: EVGIF), are in use today, reducing dependence on finite fossil fuels and putting would-be trash to good use in a green manner. EverGen, known as Canada’s Renewable Natural Gas Infrastructure Platform, is an established independent renewable energy producer which acquires, develops, builds, owns, and operates a portfolio of Renewable Natural Gas (“RNG”), waste to energy, and related infrastructure projects.

RNG is a carbon-neutral fuel that can be produced from multiple organic feedstocks, including food and animal waste and wastewater, that is processed in an anaerobic digester into products such as fertilizer and soil amendments or a biogas that is further refined to be an essentially identical replacement for conventional natural gas.

EverGen designs and builds the system and facilities, collecting organic feedstock from its partners, such as municipalities and farms. The RNG output can be used locally or sold to utilities – for instance, EverGen has several agreements with FortisBC – where the RNG is fed into the existing natural gas pipeline. At its Sea to Sky Soils facility in British Columbia, EverGen keeps organic waste out of landfills by turning it into high-quality soil amendments and blends for use on farms, gardens, and landscapes.

The adoption of these type of systems is critical as waste is mushrooming worldwide and contributing to Earth’s rising temperature. According to the U.N. Food and Agriculture Organization, about one-third of all food produced annually is either lost or wasted. In 2017, global food wasted contributed 9.3 billion metric tons of carbon dioxide-equivalent emissions. To put that in perspective, that was roughly the same amount at the total combined emissions of the U.S. and E.U. in 2017.

A study published this month on Nature.com reiterated the need for better cradle-to-grave food management, noting that emissions from food loss and waste represent half of total greenhouse gas emissions from food systems.

On February 21, EverGen announced its Sea to Sky Soils business signed multiple contracts with a British Columbia regional district for the processing of organic waste at the facility, which provide for over 10,000 tons per annum. A steward to the local community, Sea to Sky Soils is operated in partnership with Lil’wat First Nation.

According to EverGen CEO Chase Edgelow, the latest contracts are “another step towards our goal of providing solutions for over 300,000 tonnes of organic waste per annum in the region.”

The company also owns Net Zero Waste Abbotsford and Frasier Valley Biogas in British Columbia and in 2022 began its expansion east across Canada with projects in Alberta and Ontario.

For more information, visit the company’s website at www.EverGenInfra.com.

NOTE TO INVESTORS: The latest news and updates relating to EVGIF are available in the company’s newsroom at https://ibn.fm/EVGIF

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all

Posted in EverGen Infrastructure Corp. EVGIF | Leave a comment

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Hits Key Milestone in Global GBM Clinical Trial with the Enrollment of First Patient in Spain

Posted on March 24, 2023 by MissionIR
  • CNS recently enrolled the first patient in Spain in its ongoing global trial evaluating its lead drug candidate, Berubicin, for the treatment of recurrent glioblastoma multiforme (“GBM”)
  • This milestone is the culmination of years of meticulous planning and execution
  • The enrollment of this first patient follows the opening of 37 clinical trial sites of the 59 sites selected across the United States, Italy, France, Spain and Switzerland

CNS Pharmaceuticals (NASDAQ: CNSP), a clinical stage biotechnology company specializing in the development of novel treatments with a focus on brain cancer, glioblastoma and neuro-oncology, just enrolled its first patient in Spain, marking a key milestone in its GBM clinical study. Considered a potentially pivotal global trial for the company, the study seeks to evaluate Berubicin, the company’s lead drug candidate, for the treatment of recurrent glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer.

In what the CEO, John Climaco, regarded as an “encouraging enrollment pace,” CNS is on track to conduct its planned interim analysis set for mid-2023. This recent enrollment of the first patient in Spain is a major highlight of this progress (https://ibn.fm/peyQi).

“We continue to rapidly build momentum with patient enrollment across our clinical trial sites in Europe,” noted Climaco.

“We sincerely appreciate the institutions, clinicians and staff that are contributing to the conduct of this trial, and are extremely grateful to the patients that choose to participate,” he added.

In 2007, a prior developer released partial results from its Phase 1 clinical trial of Berubicin among patients with primary CNS malignancies (https://ibn.fm/VwP1V). Results, which showed 44% of patients exhibiting a clinical response, demonstrated a durable complete response, along with a stable disease in heavily pretreated patients. Results from this study would set the stage for subsequent research by CNS, leading up to the dosing of the first subject in the US in the third quarter of 2021 and the first subject in Europe in November 2022 at a site in France (https://ibn.fm/weOO6).

The enrollment of the first patient in Spain affirms CNS’ commitment to the study and highlights the years of meticulous planning and execution which have culminated in this huge milestone for the company. It followed the opening of 37 clinical trial sites of the 59 sites selected across the United States, Italy, France, Spain and Switzerland, all in a move to better understand the treatment of recurrent GBM.

CNS believes Berubicin to be the first anthracycline to appear to cross the blood-brain barrier. While it has shown incredible potential in the treatment of brain-related illnesses, CNS is exploring its potential for the treatment of other diseases, including metastatic pancreatic and ovarian cancers, as well as CNS lymphomas. By doing so, it looks to tap into the growing brain tumor therapeutics market, which is expected to hit $3.4 billion by 2025, up from $2.25 billion in 2019.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all

Posted in CNS Pharmaceuticals Inc. CNSP | Leave a comment

MissionIRNewsBreaks – Freight Technologies Inc. (NASDAQ: FRGT) Announces Board-Approved Action to Regain Compliance with NASDAQ Market Requirements

Posted on March 24, 2023 by MissionIR

Freight Technologies (NASDAQ: FRGT), a technology company offering its custom-developed Fr8App, has announced a reverse share split. The move is designed to increase the market price per share of the company’s ordinary share, thereby resulting in Freight Technologies regaining compliance with NASDAQ’s minimum bid price requirement and maintaining its NASDAQ Capital Market listing. FRGT board of directors approved the 10:1 reverse split on March 3, 2023; the split will be effective on or around March 24, 2023. According to the announcement, the company’s ordinary shares will continue to trade on NASDAQ under the symbol FRGT but will trade under a new CUSIP number: G514113113. Fr8App is an industry-leading freight-matching platform powered by AI and machine-learning that offers a real-time portal for B2B cross-border and domestic shipping within the USMCA region. “Freight Technologies is on a mission to first disrupt then revolutionize cross-border shipping and domestic shipping within the United States-Mexico-Canada region,” said Freight Technologies CEO Javier Selgas in the press release. “Maintaining NASDAQ listing is important for both the company and the shareholders. We anticipate these actions will maintain our NASDAQ listing as evermore shippers and carriers continue to turn to Freight Technologies for our unique streamlined solutions in cross border shipping and logistics.”

To view the full press release, visit https://ibn.fm/KzpO8

About Freight Technologies Inc. 

Freight Technologies is a technology company developing solutions to optimize and automate the supply chain process. Its wholly owned subsidiary Freight App Inc. (“Fr8App”) is a business-to-business, cross-border shipping marketplace in the USMCA region powered by artificial intelligence (“AI”) and machine learning. Focused on making shipping transparent and efficient, Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility and simplicity for the once-complex process of international over-the-road (“OTR”) shipping. Fr8App uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via innovative technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management and committed capacity solutions. For more information about the company, please visit www.FR8Technologies.com.

NOTE TO INVESTORS: The latest news and updates relating to FRGT are available in the company’s newsroom at https://ibn.fm/FRGT

Corporate Communications
IBN (InvestorBrandNetwork)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Freight Technologies Inc. FRGT | Leave a comment

MissionIRNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Efforts to Boost Commercial Prospects ‘Paying off in Spades’

Posted on March 24, 2023 by MissionIR

Lexaria Bioscience Corp. (NASDAQ: LEXX) is a global innovator developing and commercializing its patented DehydraTECH(TM) drug delivery technology. Lexaria is continuing and/or initiating discussions with several larger companies in Europe and North America regarding the licensed use of its technology for both consumer and pharmaceutical sectors. “The materialization of such partnerships hinges on a number of must-haves. Firstly, there must be a tangible product that draws larger companies. Secondly, The decision of whether or not to invest, and the scale of any investment, is based on how well the technologies that form the core of a company have been protected. This is where patents come in. Moreover, the further a company can take its own research, the better the deal that will be offered in terms of upfront payments, milestone payments, and royalties,” reads a recent article that contains excerpts from a LabioTech writeup. “Lexaria ticks all these boxes. Its unique technology – DehydraTECH – is not only tangible but has also been shown to enhance the performance of several categories of fat-soluble active molecules and drugs across various oral and topical product formats. The technology is also protected by a robust portfolio of 28 patents granted worldwide as of February 2023… Lastly, and perhaps most importantly, Lexaria has substantially invested in research and development (‘R&D’), an aspect of its operations that is 100% within its control. According to CEO Chris Bunka, the company has designed its applied R&D to boost its commercial prospects, and this ‘is paying off in spades,’ as it has, among others, ‘yielded almost entirely positive results.’”

To view the full article, visit https://ibn.fm/6owx5

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream through oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids, antiviral drugs, PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 28 patents granted and many patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Lexaria Bioscience Corp. LEXX | Leave a comment